Mayer Brown represents Vidara Therapeutics International Ltd. in its acquisition by Horizon Pharma, Inc. for approximately $660 million
19 March 2014
Mayer Brown, a leading global law firm, is representing Vidara Therapeutics International Ltd., a specialty pharmaceutical company organized in Ireland, in connection with its acquisition by Horizon Pharma, Inc. through a reverse merger for stock and cash valued at approximately $660 million at the time of announcement. The surviving company, to be named Horizon Pharma plc, will be listed on NASDAQ.
The Mayer Brown team included: Corporate & Securities – partners Reb Wheeler and John Berkery and associates Ugo Ude, George Rudy, Mandee Lee and Tareah Ikharo (all New York); Tax Transactions & Consulting – partners Jason Bazar and Michael Marion and associate Lucas Giardelli (all New York); Employment & Benefits – partner Ryan Liebl and associate Katherine Dean (both Chicago); Intellectual Property – partner Rich Assmus (Chicago); and Antitrust & Competition – partner Scott Perlman (Washington DC).